ATE381344T1 - Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a - Google Patents

Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a

Info

Publication number
ATE381344T1
ATE381344T1 AT00944677T AT00944677T ATE381344T1 AT E381344 T1 ATE381344 T1 AT E381344T1 AT 00944677 T AT00944677 T AT 00944677T AT 00944677 T AT00944677 T AT 00944677T AT E381344 T1 ATE381344 T1 AT E381344T1
Authority
AT
Austria
Prior art keywords
surfactant
lipid
derivative
attenuated
monophosphoryl lipid
Prior art date
Application number
AT00944677T
Other languages
German (de)
English (en)
Inventor
R Crane
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE381344T1 publication Critical patent/ATE381344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00944677T 1999-06-22 2000-06-14 Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a ATE381344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/338,182 US6491919B2 (en) 1997-04-01 1999-06-22 Aqueous immunologic adjuvant compostions of monophosphoryl lipid A

Publications (1)

Publication Number Publication Date
ATE381344T1 true ATE381344T1 (de) 2008-01-15

Family

ID=23323749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00944677T ATE381344T1 (de) 1999-06-22 2000-06-14 Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a

Country Status (9)

Country Link
US (1) US6491919B2 (enExample)
EP (1) EP1194166B1 (enExample)
JP (1) JP2003502388A (enExample)
AT (1) ATE381344T1 (enExample)
AU (1) AU775942B2 (enExample)
CA (1) CA2376829A1 (enExample)
DE (1) DE60037514T2 (enExample)
ES (1) ES2296629T3 (enExample)
WO (1) WO2000078353A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
BR0110975A (pt) * 2000-05-19 2004-03-23 Corixa Corp Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
JP2009509970A (ja) * 2005-09-22 2009-03-12 プロサイ インコーポレイテッド 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2007079193A2 (en) 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
WO2008153541A1 (en) 2006-09-26 2008-12-18 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2007303608B2 (en) 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
US9415006B2 (en) * 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
ES2566646T3 (es) * 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
DK3299030T3 (da) 2011-07-11 2022-09-05 Takeda Vaccines Inc Parenterale norovirus-vaccineformuleringer
US20150190501A1 (en) 2011-09-12 2015-07-09 Imperial Innovations Limited Methods and compositions for raising an immune response to hiv
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10420833B2 (en) 2014-05-19 2019-09-24 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
EP3069729A1 (en) 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
US11446370B2 (en) 2019-03-18 2022-09-20 Janssen Pharmaceuticals, Inc. Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
IL294445B2 (en) 2020-01-16 2023-10-01 Janssen Pharmaceuticals Inc FIMH mutant, its preparations and their use
BR112023004819A2 (pt) 2020-09-17 2023-04-18 Janssen Pharmaceuticals Inc Composições de vacinas multivalentes e seus usos
KR20250007029A (ko) 2021-01-12 2025-01-13 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
UY39710A (es) 2021-04-01 2022-09-30 Janssen Pharmaceuticals Inc Producción de bioconjugados de o18 de e. coli
WO2022251455A1 (en) * 2021-05-27 2022-12-01 Revelation Biosciences, Inc. Methods of treating or preventing allergies and chronic nasal congestion
WO2025058011A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 経鼻投与用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
US7014856B1 (en) * 1993-01-22 2006-03-21 Sloan-Kettering Institute For Cancer Research Ganglioside-KLH conjugate vaccines plus OS-21
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CN1259052A (zh) 1997-04-01 2000-07-05 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
CA2330610A1 (en) 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use

Also Published As

Publication number Publication date
EP1194166A2 (en) 2002-04-10
EP1194166B1 (en) 2007-12-19
DE60037514D1 (de) 2008-01-31
DE60037514T2 (de) 2008-12-24
AU5873800A (en) 2001-01-09
ES2296629T3 (es) 2008-05-01
CA2376829A1 (en) 2000-12-28
US20020009456A1 (en) 2002-01-24
AU775942B2 (en) 2004-08-19
US6491919B2 (en) 2002-12-10
WO2000078353A2 (en) 2000-12-28
WO2000078353A3 (en) 2001-03-15
JP2003502388A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
ATE381344T1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
ATE278419T1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
CA2205022C (fr) Adjuvant pour composition vaccinale
US20020041861A1 (en) Novel polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
EP0944397B1 (en) Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances
JPH09508349A (ja) 安定化オルトケイ酸含有調製物および生物学的調製物
HUP0004147A2 (hu) Amino-alkil-glükózamin-foszfát vegyületek és adjuvánsként, valamint immuneffektorként való alkalmazásuk
ATE157867T1 (de) Geschmacksmaskierende zusammensetzungen von ranitidin
JPS61129136A (ja) 免疫原性複合体およびその製造法
US20100278812A1 (en) Nasal immunization
PE20000574A1 (es) Articulos, metodos y composiciones para limpiar productos agricolas y proteina animal comestible
RU2074192C1 (ru) Мурамилдипептидные производные, противогриппозная вакцина
ATE192735T1 (de) Verfahren zur herstellung von aminoxyd tenside enthaltenden festen zusammensetzungen
WATARAI et al. Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes
US20020031543A1 (en) Adjuvant comprising pulmonary surfactant
JP2887733B2 (ja) アジュバント剤
EP1267937B1 (de) Polysaccharid-polypeptid konjugat
BE1024228B1 (fr) Nouvelles formulations d'adjuvants
EP1183044B1 (en) Adjuvant combinations for immunization and vaccines
KR0178422B1 (ko) 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
EP0748214B1 (fr) Liposomes, et leur utilisation notamment pour l'obtention de compositions immunomodulatrices
KR0173366B1 (ko) B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
KR0173365B1 (ko) C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
KR100406503B1 (ko) 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
CO4180620A1 (es) Proceso para preparar formulaciones solidas que contienen tensioactivos de oxido de amina, que comprende una sal so- luble en agua de acido maleico-oxido de amina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties